

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10618088
	Filing Date		2003-07-14
	First Named Inventor	Elizabeth JAFFE	
	Art Unit	1643	
	Examiner Name	Gussow, Anne	
Attorney Docket Number		001107.00363	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10618088
Filing Date	2003-07-14
First Named Inventor	Elizabeth JAFFE
Art Unit	1643
Examiner Name	Gussow, Anne
Attorney Docket Number	001107.00363

/AMG/	1	BODEY, BODEY, SIEGEL, and KAISER. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Research, 2000. Vol. 20, pages 2665-2676.	<input type="checkbox"/>
/AMG/	2	LEE, WANG, NIELSEN, WUNDERLICH, MIGUELES, CONNORS, STEINBERG, ROSENBERG, and MARINCOLA. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. Journal of Immunology, 1999. Vol. 163, pages 6262-6300.	<input type="checkbox"/>
/AMG/	3	FORNI, LOLLINI, MUSIANI, and COLOMBO. Immunoprevention of cancer: is the time ripe? Cancer Research, 2000. Vol. 60, pages 2571-2575.	<input type="checkbox"/>
/AMG/	4	GURA. Systems for identifying new drugs are often faulty. Science, 1997. Vol. 278, pages 1041-1042.	<input type="checkbox"/>
/AMG/	5	DE GRUIJL and CUIEL. Cancer vaccine strategies get bigger and better. Nature Medicine, 1999. Vol. 5, pages 1124-1125.	<input type="checkbox"/>
/AMG/	6	CHATTERJEE, FOON, and KOHLER. Idiotype antibody immunotherapy of cancer. Cancer Immunology Immunotherapy, 1994. Vol. 38, pages 75-82.	<input type="checkbox"/>
/AMG/	7	Non-Final Office Action dated March 10, 2010 in co-pending U.S. Patent Application No. 12/210,604.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Anne M. Gussow/	Date Considered	05/25/2010
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.